| Clear cell renal cell carcinoma: from biology to treatment AM Kase, DJ George, S Ramalingam Cancers 15 (3), 665, 2023 | 35 | 2023 |
| Novel therapeutic strategies for CDK4/6 inhibitors in metastatic castrate-resistant prostate cancer AM Kase, JA Copland III, W Tan OncoTargets and therapy, 10499-10513, 2020 | 19 | 2020 |
| Breast cancer metastasis to the bladder: a literature review AM Kase, D Menke, W Tan Case Reports 2018, bcr-2017-222031, 2018 | 14 | 2018 |
| A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancer EE Parent, AM Kase Cancers 14 (17), 4276, 2022 | 9 | 2022 |
| The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer AM Kase, W Tan, JA Copland III, H Cai, EE Parent, RA Madan Cancers 14 (6), 1361, 2022 | 8 | 2022 |
| Complete response in patients with lung-only metastatic prostate cancer: outcome analysis AM Kase, JA Copland III, Q Zhai, W Tan Clinical Genitourinary Cancer 20 (6), e485-e489, 2022 | 4 | 2022 |
| Efficacy of gemcitabine in combination with nanoparticle a lbumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review AM Kase, AG Azzouqa, S Kochuveettil, G Colon‐Otero Cancer medicine 12 (8), 9434-9438, 2023 | 3 | 2023 |
| Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate. AM Mahmoud, P Navin, M Muniz, F Quevedo, J Orme, JR Andrews, ... Journal of Clinical Oncology 42 (4_suppl), 49-49, 2024 | 2 | 2024 |
| Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells AM Kase, HS Murthy, MA Kharfan-Dabaja Bone Marrow Transplantation 55 (7), 1464-1465, 2020 | 2 | 2020 |
| A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer … O Mosalem, W Tan, AH Bryce, RS Dronca, DS Childs, LC Pagliaro, ... Prostate Cancer and Prostatic Diseases, 1-7, 2024 | 1 | 2024 |
| Enfortumab vedotin treatment regimens and efficacy in urothelial carcinoma: The Mayo Clinic experience. T Ballouz, N Tripathi, SAA Naqvi, A Saxena, A Bibi, AML Kase, DS Childs, ... Journal of Clinical Oncology 42 (4_suppl), 627-627, 2024 | 1 | 2024 |
| Complete response to pembrolizumab in a patient with dermatomyositis and MMR deficient ovarian cancer: A case report ML Valls, AM Kase, R Patel, B Wang, R Aggarwal, G Colon-Otero Gynecologic Oncology Reports 41, 2022 | 1 | 2022 |
| Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T AM Kase, MA Kharfan‐Dabaja, A Donaldson, J Elliott, T Sher Clinical Case Reports 10 (4), e05572, 2022 | 1 | 2022 |
| Neuropsychiatric manifestations of lymphoma-associated cerebral glucose hypometabolism can be reversed by intensive glucose supplementation AM Kase, C Bullock, R Parrondo, M Alhaj Moustafa, M Iqbal, KD Li, ... Blood and Lymphatic Cancer: Targets and Therapy, 17-21, 2022 | 1 | 2022 |
| Patient-derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for the management of metastatic castration-resistant prostate cancer AM Kase, J Gleba, JL Miller, E Miller, J Petit, MT Barrett, Y Zhou, ... Molecular Cancer Therapeutics 23 (6), 823-835, 2024 | | 2024 |
| Association of change in PSMA avid tumor burden during 177Lu-PSMA-617 therapy with overall survival: Should mid-point PET become standard protocol? N Maufort, J Zipoy, M Muniz, P Navin, D Childs, A Kendi, A Mahmoud, ... Journal of Nuclear Medicine 65 (supplement 2), 2424-2424, 2024 | | 2024 |
| Correlation of baseline Ga-68 PSMA PET bone tumor volume with risk of bone marrow related side effects after receiving treatment of Lu-177 PSMA J Zipoy, N Maufort, M Muniz, P Navin, D Childs, A Kendi, A Mahmoud, ... Journal of Nuclear Medicine 65 (supplement 2), 2423-2423, 2024 | | 2024 |
| Efficacy of first line (1L) poly ADP-ribose polymerase inhibitors (PARPi) in combination with androgen pathway inhibitors (API) by homologous recombination repair (HRR) genes … A Bibi, SAA Naqvi, MA Khan, A Raina, KZR Khakwani, J Orme, DS Childs, ... Journal of Clinical Oncology 42 (16_suppl), e17059-e17059, 2024 | | 2024 |
| Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going M Muniz, CL Loprinzi, JJ Orme, RM Koch, AM Mahmoud, AM Kase, ... Cancer Treatment Reviews, 102748, 2024 | | 2024 |
| Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment. M Muniz, AO Sartor, AM Mahmoud, J Orme, JY Kwon, JR Andrews, ... Journal of Clinical Oncology 42 (4_suppl), 175-175, 2024 | | 2024 |
